Literature DB >> 26258765

New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines.

William H Shrank1, Jane F Barlow1, Troyen A Brennan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26258765     DOI： 10.1001/jama.2015.10017

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  15 in total

1.  Has The Era Of Slow Growth For Prescription Drug Spending Ended?

Authors:  Murray Aitken; Ernst R Berndt; David Cutler; Michael Kleinrock; Luca Maini
Journal:  Health Aff (Millwood)       Date:  2016-09-01       Impact factor: 6.301

2.  Rising Drug Costs Drives the Growth of Pharmacy Benefit Managers Exclusion Lists: Are Exclusion Decisions Value-Based?

Authors:  Joshua P Cohen; Christelle El Khoury; Christopher-Paul Milne; Sandra M Peters
Journal:  Health Serv Res       Date:  2017-10-18       Impact factor: 3.402

3.  Measuring the Value of Pharmaceuticals in the US Health System.

Authors:  Surrey M Walton; Anirban Basu; John Mullahy; Samuel Hong; Glen T Schumock
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

Review 4.  Recent Update to the US Cholesterol Treatment Guidelines: A Comparison With International Guidelines.

Authors:  Matthew Nayor; Ramachandran S Vasan
Journal:  Circulation       Date:  2016-05-03       Impact factor: 29.690

5.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.

Authors:  Elodie Weider; Delia Susan-Resiga; Rachid Essalmani; Josée Hamelin; Marie-Claude Asselin; Surendra Nimesh; Yahya Ashraf; Keith L Wycoff; Jianbing Zhang; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2016-06-08       Impact factor: 5.157

6.  Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.

Authors:  Christopher P Cannon; Irfan Khan; Alexa C Klimchak; Matthew R Reynolds; Robert J Sanchez; William J Sasiela
Journal:  JAMA Cardiol       Date:  2017-09-01       Impact factor: 14.676

7.  Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.

Authors:  Charles J Glueck; Parth Shah; Naila Goldenberg; Marloe Prince; Kevin Lee; Vybhav Jetty; Ashwin Kumar; Michael Goldenberg; Ping Wang
Journal:  Lipids Health Dis       Date:  2016-03-12       Impact factor: 3.876

Review 8.  Lipids, blood pressure and kidney update 2015.

Authors:  Maciej Banach; Wilbert S Aronow; Maria-Corina Serban; Jacek Rysz; Luminita Voroneanu; Adrian Covic
Journal:  Lipids Health Dis       Date:  2015-12-30       Impact factor: 3.876

9.  Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.

Authors:  Parth Shah; Charles J Glueck; Vybhav Jetty; Naila Goldenberg; Matan Rothschild; Rashid Riaz; Gregory Duhon; Ping Wang
Journal:  Lipids Health Dis       Date:  2016-08-18       Impact factor: 3.876

10.  Statin Intensity or Achieved LDL? Practice-based Evidence for the Evaluation of New Cholesterol Treatment Guidelines.

Authors:  Elsie Gyang Ross; Nigam Shah; Nicholas Leeper
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.